Insulin Signaling Pathway in Neurodegeneration

Overview

The insulin signaling pathway represents one of the most critical molecular hubs in neurodegenerative disease pathogenesis. Once considered primarily a metabolic regulator, insulin signaling in the brain is now understood to be essential for neuronal survival, synaptic plasticity, cognitive function, and cellular energy homeostasis. The recognition that Alzheimer’s disease (AD) represents “Type 3 Diabetes” has transformed our understanding of the insulin-neurodegeneration axis, with profound implications for diagnosis and therapy ^{4Stricturing Crohn's Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions.2024 · Gastroenterology · DOI 10.1053/j.gastro.2023.07.014 · PMID 37507073Open reference}. ^{1Uncovering the intricacies of IGF-1 in Alzheimer's disease: new insights from regulation to therapeutic targeting.2025 · Inflammopharmacology · DOI 10.1007/s10787-025-01641-0 · PMID 39883327Open reference}

Brain insulin resistance is now documented as an early and progressive feature in Alzheimer’s disease, Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), establishing insulin signaling dysfunction as a convergent pathological mechanism across neurodegenerative disorders. This convergence provides therapeutic opportunities for intervention at a fundamental regulatory level ^{5Realist evaluations: relevance to pharmacy practice and education.2025 · The International journal of pharmacy practice · DOI 10.1093/ijpp/riaf111 · PMID 41222411Open reference}. ^{2Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.2025 · Acta neurologica Belgica · DOI 10.1007/s13760-024-02706-7 · PMID 39762668Open reference}

Historical Context

The link between diabetes and cognitive decline was first suggested in the 1980s, but the formal “Type 3 Diabetes” hypothesis was articulated by de la Monte and colleagues in 2005, proposing that Alzheimer’s disease represents a form of diabetes that specifically affects the brain ^{4Stricturing Crohn's Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions.2024 · Gastroenterology · DOI 10.1053/j.gastro.2023.07.014 · PMID 37507073Open reference}. This hypothesis has gained substantial support over the past two decades, with converging evidence from epidemiological studies, postmortem brain analyses, cerebrospinal fluid biomarker studies, and neuroimaging investigations. ^{3Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis.2019 · Disease models & mechanisms · DOI 10.1242/dmm.036590 · PMID 31036560Open reference}

The insulin signaling pathway in the brain was historically understudied relative to peripheral insulin signaling, partly due to the assumption that the brain was insulin-independent. The discovery of insulin receptors throughout the brain, particularly dense in the hippocampus, cortex, and hypothalamus, fundamentally challenged this assumption and opened a new field of investigation ^{5Realist evaluations: relevance to pharmacy practice and education.2025 · The International journal of pharmacy practice · DOI 10.1093/ijpp/riaf111 · PMID 41222411Open reference}.

The Insulin Signaling Cascade in the Brain

Receptor Architecture

The brain expresses two insulin receptor isoforms derived from alternative splicing:

• IR-A: Predominant isoform in the brain, binds both insulin and insulin-like growth factor-2 (IGF-2)

• IR-B: More common in peripheral tissues, primarily binds insulin

These receptors are highly expressed on neurons, astrocytes, and microglia, with regional variations reflecting the functional importance of insulin signaling in specific brain circuits. Notably, the hippocampus and entorhinal cortex—regions critical for memory and vulnerable to early AD pathology—show particularly high insulin receptor density. Importantly, insulin receptors in the brain are strategically positioned at synapses, where they regulate synaptic plasticity and plasticity-related signaling cascades in response to neuronal activity.

Core Signaling Pathways

Upon insulin binding to its receptor, two major downstream cascades are activated:

1. PI3K/Akt Pathway: The primary metabolic and survival pathway

   • IRS-1 (Insulin Receptor Substrate 1) mediates receptor-effector coupling

   • PI3K (Phosphoinositide 3-kinase) generates PIP3, activating Akt/PKB

   • Akt phosphorylates multiple downstream targets including mTOR, GSK3β, and FOXO transcription factors

2. MAPK/ERK Pathway: The growth and plasticity pathway

   • Ras-RAF-MEK-ERK cascade activates

   • Regulates neuronal differentiation, synaptic plasticity, and stress responses

The balance between these pathways determines cellular outcomes—survival versus proliferation, plasticity versus rigidity, metabolism versus growth.

Pathway Diagram

flowchart TD
    A["Insulin"] --> B["Insulin Receptor IR-A/IR-B"]
    B --> C["IRS-1/2"]
    C --> D{"PI3K/Akt Pathway"}
    C --> E{"MAPK/ERK Pathway"}

    D --> F["PI3K"]
    D --> G["Akt/PKB"]

    E --> H["Ras"]
    E --> I["RAF"]
    E --> J["MEK"]
    E --> K["ERK1/2"]

    G --> L["mTORC1"]
    G --> M["GSK3beta Inhibition"]
    G --> N["FOXO Inactivation"]
    G --> O["CREB Activation"]
    G --> P["Bad Phosphorylation"]

    L --> Q["Protein Synthesis"]
    L --> R["Autophagy Regulation"]

    M --> S["Tau Phosphorylation down"]
    M --> T["Glycogen Synthase Activation"]

    N --> U["Apoptosis Inhibition"]
    O --> V["Gene Transcription"]
    P --> W["Mitochondrial Survival"]

    X["Abeta Oligomers"] -.->|"Inhibit"| B
    X -.->|"Activate"| Y["IDE Inhibition"]
    Y --> Z["Abeta Clearance down"]

    AA["p-Tau"] -.->|"Impair"| C
    BB["Chronic Inflammation"] -.->|"Cause"| CC["IRS-1 Serine Phosphorylation"]
    CC -.->|"Inhibit"| D
    DD["Oxidative Stress"] -.->|"Damage"| C

    B --> EE["Insulin Resistance"]
    EE --> FF["Synaptic Dysfunction"]
    EE --> GG["Cognitive Decline"]
    EE --> HH["Metabolic Dysfunction"]
    EE --> II["Autophagy Failure"]
    EE --> JJ["Mitochondrial Dysfunction"]

    FF --> KK["Abeta Accumulation"]
    GG --> LL["Tau Hyperphosphorylation"]

Key Molecular Components

Brain Insulin Resistance: The Central Pathological Feature

Mechanisms of Insulin Resistance in Neurodegeneration

Brain insulin resistance develops through multiple convergent mechanisms:

1. Amyloid-β-mediated inhibition: Aβ oligomers directly bind to insulin receptors, acting as competitive antagonists. This interaction has been demonstrated both in vitro and in vivo, with Aβ-IR complexes isolated from AD brains ^{2Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.2025 · Acta neurologica Belgica · DOI 10.1007/s13760-024-02706-7 · PMID 39762668Open reference}5. Soluble Aβ oligomers (specifically Aβ*56) have been shown to cause synaptic insulin resistance by disrupting insulin receptor clustering at dendritic spines, impairing local insulin signaling during synaptic activity.

2. Tau pathology-mediated dysfunction: Hyperphosphorylated tau disrupts insulin receptor trafficking and signaling at the synapse. The tau-insulin interaction creates a vicious cycle where each pathology exacerbates the other ^{2Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.2025 · Acta neurologica Belgica · DOI 10.1007/s13760-024-02706-7 · PMID 39762668Open reference}6. Tau pathology affects insulin signaling through multiple mechanisms: (1) tau physically interacts with IRS-1, sequestering it away from the insulin receptor; (2) tau pathology disrupts actin cytoskeleton dynamics required for proper receptor trafficking; (3) tau-mediated synaptic loss removes insulin receptor-bearing synapses.

3. Inflammatory-mediated serine phosphorylation: Chronic neuroinflammation activates kinases (IKKβ, JNK) that phosphorylate IRS-1 on serine residues, inhibiting downstream signaling. This mechanism links the well-documented neuroinflammation in AD and PD to insulin signaling dysfunction ^{2Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.2025 · Acta neurologica Belgica · DOI 10.1007/s13760-024-02706-7 · PMID 39762668Open reference}7. The inflammatory cytokine TNF-α is particularly potent in inducing IRS-1 serine phosphorylation, and elevated TNF-α has been documented in both AD and PD brains.

4. Oxidative stress and mitochondrial dysfunction: Reactive oxygen species damage insulin receptor substrates and downstream signaling components, creating a metabolic deficit that compounds other pathological changes ^{2Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.2025 · Acta neurologica Belgica · DOI 10.1007/s13760-024-02706-7 · PMID 39762668Open reference}8. Oxidative stress both results from and exacerbates insulin resistance through multiple pathways including ROS-mediated inhibition of insulin receptor tyrosine kinase activity and damage to IRS-1 phosphotyrosine binding domains.

5. Lipotoxicity: Ceramide accumulation in neurons induces insulin resistance through protein phosphatase 2A activation and IRS-1 serine phosphorylation, establishing another mechanistic link between metabolic dysfunction and neurodegeneration. Elevated ceramide levels have been documented in AD and PD brains, and ceramides can directly induce neuronal apoptosis while simultaneously causing insulin resistance.

6. Endoplasmic reticulum stress: The unfolded protein response (UPR) activated in neurodegenerative conditions interferes with insulin signaling through multiple mechanisms including eIF2α phosphorylation that blocks IRS-1 translation and XBP1 splicing that alters expression of lipid metabolism genes affecting insulin receptor function.

Regional Vulnerability

Brain insulin resistance shows regional specificity:

• Hippocampus: Early and severe insulin resistance; correlates with memory impairment

• Entorhinal Cortex: Vulnerable to both insulin resistance and tau pathology; early AD changes

• Frontal Cortex: Insulin resistance contributes to executive dysfunction

• Substantia Nigra: Dopaminergic neurons show particular vulnerability to insulin signaling impairment in PD

Alzheimer’s Disease and the Insulin Axis

Insulin Resistance as an Early Biomarker

Multiple studies have established that brain insulin resistance precedes clinical symptoms:

• CSF biomarkers: Reduced CSF insulin levels and increased IRS-1 serine phosphorylation correlate with amyloid and tau pathology in preclinical AD ^{2Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.2025 · Acta neurologica Belgica · DOI 10.1007/s13760-024-02706-7 · PMID 39762668Open reference}9

• Neuroimaging: FDG-PET shows hypometabolism in insulin-sensitive regions even before cognitive symptoms

• Postmortem studies: Insulin receptor density and signaling are reduced in MCI and early AD brains

The Amyloid-Insulin Feedback Loop

Aβ and insulin signaling interact in a bidirectional pathological loop:

1. Aβ oligomers inhibit insulin signaling through direct receptor binding

2. Impaired insulin signaling reduces Aβ clearance via decreased IDE (insulin-degrading enzyme) activity

3. Reduced Aβ clearance leads to increased Aβ accumulation

4. Increased Aβ further inhibits insulin signaling

This vicious cycle accelerates disease progression and represents a therapeutic target for breaking the self-perpetuating pathology.

Tau Hyperphosphorylation via Insulin Signaling Dysregulation

GSK3β hyperactivity resulting from insulin signaling impairment promotes tau hyperphosphorylation at multiple sites (Thr181, Ser396, PHF-6 motifs). The PI3K/Akt pathway normally inhibits GSK3β; when this inhibition is lost, tau pathology accelerates ^{3Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis.2019 · Disease models & mechanisms · DOI 10.1242/dmm.036590 · PMID 31036560Open reference}0.

Clinical evidence supports this connection:

• Patients with type 2 diabetes have increased risk of AD

• Diabetes mellitus is associated with greater tau pathology at autopsy

• Insulin sensitizers reduce tau phosphorylation in animal models

Clinical Trials Targeting Insulin Signaling

Parkinson’s Disease and Insulin Dysregulation

Evidence of Brain Insulin Resistance in PD

Parkinson’s disease shows distinct insulin signaling abnormalities:

1. Dopaminergic neuron vulnerability: Substantia nigra pars compacta neurons are particularly sensitive to insulin resistance, with insulin receptors highly expressed on these cells. Insulin signaling supports mitochondrial function and protects against oxidative stress in dopaminergic neurons.

2. α-Synuclein-insulin interaction: α-Synuclein can interfere with insulin receptor trafficking and signaling. Conversely, insulin signaling dysfunction may promote α-synuclein aggregation through impaired autophagy and increased oxidative stress.

3. LRRK2-Insulin crosstalk: LRRK2 (leucine-rich repeat kinase 2) mutations, the most common genetic cause of familial PD, modulate insulin signaling pathways. LRRK2 can phosphorylate IRS-1, potentially contributing to insulin resistance in PD patients with LRRK2 mutations.

4. Clinical correlations: Insulin resistance in PD correlates with:

   • More severe motor symptoms (higher UPDRS scores)

   • Cognitive impairment and dementia risk

   • Faster disease progression

Therapeutic Implications for PD

Several therapeutic strategies targeting insulin signaling are being investigated for PD:

• GLP-1 receptor agonists: Exenatide and liraglutide have shown promise in PD clinical trials, with improvements in motor scores observed in some studies

• Intranasal insulin: Being explored for PD cognitive symptoms

• Insulin sensitizers: Pioglitazone being investigated for neuroprotection

Amyotrophic Lateral Sclerosis

Motor neurons show high metabolic demands requiring robust insulin signaling:

• Energy homeostasis: Motor neurons are particularly dependent on precise metabolic regulation; insulin signaling impairment contributes to vulnerability

• Metabolic dysfunction: ALS patients often show insulin resistance and altered glucose metabolism

• Therapeutic targeting: IGF-1 (insulin-like growth factor-1) has been explored as a neuroprotective agent in ALS, with mixed results in clinical trials

Therapeutic Strategies

Pharmacological Interventions

Approved and Repurposed Agents

1. GLP-1 Receptor Agonists

   • Liraglutide, exenatide, semaglutide

   • Cross blood-brain barrier at high doses

   • Activate insulin signaling through GLP-1 receptors on neurons

   • Ongoing trials in AD and PD

2. Thiazolidinediones (PPARγ agonists)

   • Pioglitazone, rosiglitazone

   • Enhance insulin sensitivity

   • Anti-inflammatory effects

   • Mixed clinical trial results

3. Intranasal Insulin

   • Bypasses blood-brain barrier

   • Direct CNS delivery

   • Phase 2 trials showing cognitive benefit in AD

Investigational Approaches

• IRS-1 serine phosphorylation inhibitors: Restore downstream signaling

• Akt activators: Bypass defective IRS-1 to activate survival pathways

• mTOR modulators: Balance autophagy and protein synthesis

• Gene therapy: Target neurotrophic factors downstream of insulin signaling

Lifestyle Interventions

1. Ketogenic Diet: Improves brain insulin sensitivity; may reduce amyloid and tau pathology

2. Intermittent Fasting: Enhances insulin sensitivity; activates autophagy

3. Exercise: Improves peripheral and brain insulin sensitivity

4. Sleep Optimization: Sleep deprivation induces insulin resistance

Emerging Therapeutics

Molecular Mechanisms: Detailed Analysis

Autophagy Regulation

The insulin signaling pathway critically regulates autophagy through mTORC1 inhibition. In insulin resistance:

• mTORC1 becomes overactive (due to reduced Akt inhibition)

• Autophagy is suppressed

• Protein aggregates (Aβ, τ, α-syn) accumulate

• Cellular clearance mechanisms fail

This creates a feedforward loop where accumulated aggregates further impair insulin signaling.

Synaptic Plasticity

Insulin signaling is essential for synaptic plasticity:

• Akt regulates AMPA receptor trafficking

• GSK3β modulates NMDA receptor function

• FOXO controls synaptic protein expression

• mTOR regulates local protein synthesis at synapses

Insulin resistance therefore directly impairs the cellular basis of learning and memory.

Mitochondrial Function

Insulin signaling supports mitochondrial health through:

• PGC-1α activation (mitochondrial biogenesis)

• FoxO3 regulation of antioxidant genes

• Akt-mediated survival signaling

Insulin resistance leads to mitochondrial dysfunction, increasing oxidative stress and energy failure.

Neuroinflammation

The relationship between insulin resistance and neuroinflammation is bidirectional:

• Inflammatory cytokines (TNF-α, IL-1β) cause IRS-1 serine phosphorylation

• This creates insulin resistance

• Insulin resistance promotes more inflammation

• Microglia become dysregulated

Breaking this cycle is central to therapeutic approaches.

Biomarkers and Diagnostic Applications

Current Biomarker Landscape

Emerging Diagnostic Approaches

• PET with insulin receptor ligands: Visualize brain insulin receptor availability

• MRI with arterial spin labeling: Assess cerebral insulin sensitivity

• Multiplex biomarker panels: Combine insulin signaling metabolites with established AD/PD biomarkers

Research Gaps and Future Directions

Unresolved Questions

1. Temporal relationship: Does insulin resistance cause neurodegeneration, or does neurodegeneration cause insulin resistance?

2. Cell-type specificity: How do different brain cell types (neurons, astrocytes, microglia) contribute to brain insulin resistance?

3. Mechanistic redundancy: Are there compensatory mechanisms that could be therapeutically exploited?

4. Personalized medicine: Which patient subgroups will respond best to insulin-targeting therapies?

Priority Research Areas

• Development of brain-penetrant insulin sensitizers

• Biomarker development for patient selection

• Combination therapy approaches (insulin + anti-amyloid, insulin + anti-tau)

• Understanding sex differences in insulin-neurodegeneration relationships